Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
Andres Ramirez-GameroHumberto Martínez-CorderoBrady Ernesto Beltrán-GárateJorge A FlorindezLuis E Malpica-CastilloJorge J CastilloPublished in: American journal of hematology (2024)
Combination chemotherapy regimens, such as EPOCH, are recommended. The addition of bortezomib, lenalidomide, or daratumumab might improve outcomes. Including PBL patients and their participation in prospective clinical trials is warranted.
Keyphrases
- newly diagnosed
- multiple myeloma
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- physical activity
- diffuse large b cell lymphoma
- prognostic factors
- type diabetes
- randomized controlled trial
- metabolic syndrome
- low dose
- adipose tissue
- high dose
- rectal cancer
- phase ii
- glycemic control